TY - JOUR
T1 - tPA in acute ischemic stroke
T2 - United States experience and issues for the future
AU - Alberts, Mark J.
PY - 1998/9
Y1 - 1998/9
N2 - The approval of tissue plasminogen activator (tPA) for treatment of patients with ischemic stroke in the United States marked the first therapy proven to reverse or limit the effects of an acute stroke. Despite this approval and the lack of an alternative therapy, the use of tPA in stroke has been quite low. Several explanations for this underutilization have been identified, including lack of patient awareness, potential complications, infrastructure deficiencies, and physician concerns. This article explores these issues and suggests strategies for improving the use of tPA as an acute therapy in stroke.
AB - The approval of tissue plasminogen activator (tPA) for treatment of patients with ischemic stroke in the United States marked the first therapy proven to reverse or limit the effects of an acute stroke. Despite this approval and the lack of an alternative therapy, the use of tPA in stroke has been quite low. Several explanations for this underutilization have been identified, including lack of patient awareness, potential complications, infrastructure deficiencies, and physician concerns. This article explores these issues and suggests strategies for improving the use of tPA as an acute therapy in stroke.
UR - http://www.scopus.com/inward/record.url?scp=0031655731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031655731&partnerID=8YFLogxK
U2 - 10.1212/wnl.51.3_suppl_3.s53
DO - 10.1212/wnl.51.3_suppl_3.s53
M3 - Article
C2 - 9744836
AN - SCOPUS:0031655731
SN - 0028-3878
VL - 51
SP - S53-S55
JO - Neurology
JF - Neurology
IS - 3 SUPPL.
ER -